GLENMARK PHARMACEUTICALS
GLENMARK.NS
₹ 1,545.40
1%
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd is a Small Cap stock that belongs to the Pharmaceuticals & Drugs sector. The current live share price of Glenmark Pharma is ₹ 1,545.40 that is ₹ 14.00 -0.9% with respect to the previous day’s close price. The stock price of Glenmark Pharma was last updated 4 seconds ago.
Glenmark Pharma Stock Price Performance
In the below section, we have evaluated the stock’s price performance for the last traded day as well as historical time frames.
Glenmark Pharma Live Share Price Analysis
GLENMARK PHARMACEUTICALS
₹ 1,545.40
Open ₹ 1,563.00
High ₹ 1,563.80
Marketcap 436.09B
Close ₹ 1,545.40
Low ₹ 1,543.00
Volume ₹ 283,922.00
The stock of Glenmark Pharmaceuticals Ltd strated the trade at an Open price of ₹ 1,563.00 when the trading at exchange began for the day. It touched an Intraday High price of ₹ 1,563.80 and an Intraday Low price of ₹ 1,543.00%. As per last updated 4 seconds ago, the Shares of Glenmark Pharma were trading at a price of ₹ 1,545.40 which is ₹ 14.00 -0.9% as compared the price ₹ 1,559.40 at which the stock close on the previous trading day. The total traded volume for the day stood at 283,922 number of shares.
Candlestick Chart of Glenmark Pharma Share Price Movements
The following candlestick Chart of the Stock shows how the Open, High, Low, Close (OHLC) Price of the share has performed in the last month (30-day period).
Historical Performance of Glenmark Pharma Shares
| 52 Week Range | Price | 52 Weeks Low | 52 Weeks High |
|---|---|---|---|
| ₹ 1,545.40 | ₹ 771.00 | ₹ 1,830.95 |
Here is Glenmark Pharma’s price performance analysis over the last year. The stock has seen the 52 weeks high price level of ₹ 1,830.95. On the lower side, the stock has been to the 52 weeks low price level of ₹ 771.00. It’s last traded price was ₹ 1,545.40 as on last update 5 seconds ago. The one-year line chart clearly shows how the price of Glenmark Pharma’s stock has moved in the last twelve months.
The Company has posted an earnings of ₹ -36.02 per share (EPS TTM) in the trailing twelve months period. Glenmark Pharma’s last annual dividend rate was 2.5%, which translates to a 0.16% of annual dividend yield.
Line Chart of Glenmark Pharma Stock Price
Here is the chart of stock price performance for the last one year. You can also view the price performance of a different period by selecting the time frame from the top right corner.
Companies Similar to Glenmark Pharma
Glenmark Pharmaceuticals Ltd belongs to the Pharmaceuticals & Drugs sector. It has several competitors in the same industry. The snapshot of the live share price of some of the companies similar to Glenmark Pharma are listed below. You can click and view the details of stock analysis, current and historical share price, company background information about each company.
Share Price Snapshot Companies Similar to Glenmark Pharma
Select list of companies is given below. To view more about the Industry and see other companies from Pharmaceuticals & Drugs Industry, click on the industry name.
About Glenmark Pharma
Glenmark Pharmaceuticals Ltd is a Glenmark Group Company. The company operates in the Pharmaceuticals & Drugs sector. It is a global pharmaceutical company. Incorporated in 1977, it has around 44 years of operations. Glenmark Pharma live share price is ₹ 1,545.40. It is a Small Cap stock and had a market capitalization of ₹ 436,093,353,984.00 as on 5 seconds ago.
- Glenmark Pharma is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
- Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
- It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development.
- It is focused on developing and marketing branded and generic formulations.
- It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology.
- Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada.
- Its products are primarily marketed in the United States and Western Europe.
- It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries.
- It operates over five research and development (R&D) centers.
The registered office of Glenmark Pharma is located in Mumbai, Maharashtra. The registrar and share transfer agent for Glenmark Pharma is K FIN Technologies Pvt Ltd. The Stock Exchanges on which shares of Glenmark Pharmaceuticals Ltd is listed includes BSE, NSE, MCX.
GLENMARK PHARMACEUTICALS
Status: Active
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 14989
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
| Address | Glenmark House, Mumbai, India |
| Country | India |
| Phone | 91 22 4018 9999 |
| Website | https://www.glenmarkpharma.com |
Glenmark Pharma Recent News
No Recent News found for Glenmark Pharmaceuticals Ltd.